Second cancer after treatment of malignant germ-cell tumors.
Patients cured of a malignant germ-cell tumor are at a significantly increased relative risk (RR, 1.3-2.1) of developing a new malignancy, the most frequent second cancer being a new germ-cell cancer. The exact role of modern treatment of germ-cell malignancies as an etiological factor of a subsequent cancer has not yet been defined. The relative risk of developing a new non-germ-cell cancer, however, seems especially high after intensive cytotoxic treatment.
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
S D
SD
Fosså
E H
EH
Wanderås
K
K
Heimdal
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D002278:Carcinoma in Situ / Q000097:blood / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D018237:Germinoma / Q000097:blood / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008297:Male; D009361:Neoplasm Invasiveness; D016609:Neoplasms, Second Primary / Q000097:blood / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D009919:Orchiectomy; D011879:Radiotherapy Dosage; D012307:Risk Factors; D013736:Testicular Neoplasms / Q000097:blood / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D013997:Time Factors
D014408:Biomarkers, Tumor; D005640:Follicle Stimulating Hormone